30 Jun 2021
Award-winning consulting firm Fact.MR has recently published an extensive report on the global market for hyperthermia cancer treatment for the forecast period of 2021-2031. According to the study, the market is anticipated to accrue impressive gains, expanding at a CAGR of around 6% to surpass a valuation of US$ 250 million by 2031. Rising cancer prevalence is attributed as the chief growth driver for this market.
The International Agency for Research on Cancer (IARC) estimates that, globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease, respectively. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. Also, according to the World Health Organization, breast cancer is the most commonly occurring cancer in women and the second-most common cancer overall. Over 2 million new cases of breast cancer were diagnosed across the world in 2018. Hence, the scope for incorporating sophisticated treatments is increasing, paving way for enhanced adoption of hyperthermia cancer treatment.
Furthermore, various governmental initiatives to fund extensive cancer research programs are proving to be a boon for market growth. For instance, in April 2016, the U.S. Government allotted US$ 5.2 billion to the National Cancer Institute (NCI) for cancer research and training. This has enabled the U.S. healthcare system to deploy a host of advanced cancer treatment and diagnosis solutions.
“Rising demand for improving clinical outcomes and inflicting minimal patient discomfort is prompting healthcare providers to deploy a broad range of advanced surgical and therapeutic options, including high intensity focused ultrasound (HIFU), widening the growth prospects of market players,” says a Fact.MR analyst.
Fact.MR’s has profiled the following hyperthermia cancer treatment solution providers in its research report: PYREXAR Medical, Celsius42 GmbH, Hydrosun GmbH, Oncotherm Kft., Andromedic S.r.l., Yamamoto Vinita Co. Ltd, Chongqing Haifu Medical Technology Co. Ltd., innoMedicus Ltd., Gamida-Cell Ltd., and RanD. Some key expansion strategies deployed by the afore mentioned players include strengthening distribution networks and introducing new approaches to treat and diagnose potential cancers.
Fact.MR, in its new offering, presents an unbiased analysis of the hyperthermia cancer treatment market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of device (infrared devices, ultrasound devices, microwave devices, and others), treatment method (loco-regional and whole body), application (breast cancer, liver cancer, soft tissue sarcoma, head & neck tumors, prostate cancer, and others) and enduser (hospitals & specialty clinics, ambulatory surgical centers, and others) across five major regions of the world (North America, Europe, Latin America, AsiaPacific, and the Middle East & Africa).
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
For more information, refer to our market research report or contact the PR author.
Shambhu Nath Jha
Fact.MR
Sr. Consultant – Healthcare
E-mail: shambhu@factmr.com
Hyperthermia Cancer Treatment Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.